Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 37

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 37
---
 overall company and individual executive performance to make final compensation decisions, which were recommended to the Board of Directors for approval (in the case of the CEO). The criteria the Committee used for selecting peers included: • Public commercial biopharmaceutical companies with a product on the market; • Market capitalization values generally between $600 million and $5.4 billion; • Companies with annual revenue generally between $200 million and $2 billion; and • Companies with 225-2,000 employees reflecting other organizations of similar scale and complexity. Using these criteria, the following companies were determined to comprise the Company’s peer group (the “Peer Group”):

| ​ | ​ | ACADIA Pharmaceuticals Inc.     | ​ | ​ | ​ | ANI Pharmaceuticals, Inc.         | ​ | ​ | ​ | Emergent Biosolutions Inc.         | ​ | ​ | ​ | Ligand Pharmaceuticals Incorporated | ​ | ​ |
| ​ | ​ | Alkermes Plc                    | ​ | ​ | ​ | Collegium Pharmaceutical, Inc.    | ​ | ​ | ​ | Halozyme Therapeutics, Inc.        | ​ | ​ | ​ | Pacira Biosciences, Inc.            | ​ | ​ |
| ​ | ​ | Amicus Therapeutics, Inc.       | ​ | ​ | ​ | Corcept Therapeutics Incorporated | ​ | ​ | ​ | Harmony Biosciences Holdings, Inc. | ​ | ​ | ​ | PTC Therapeutics, Inc.              | ​ | ​ |
| ​ | ​ | Amphastar Pharmaceuticals, Inc. | ​ | ​ | ​ | Dynavax Technologies Corporation  | ​ | ​ | ​ | Ironwood Pharmaceuticals, Inc.     | ​ | ​ | ​ | Ultragenyx Pharmaceutical Inc.      | ​ | ​ |

Compared to the Peer Group, for 2024, the Company was at the 51 st percentile of revenues, 39 th percentile of market capitalization, 67 th percentile for 1 year total shareholder return, and the 61 st percentile of Peer Group headcount. Elements of Executive Compensation The main components of our executive compensation program are: • Base salary; • Annual cash bonus; and • Long-term incentives — equity awards in the form of options, restricted stock units (“RSUs”), and performance stock units (“PSUs”).

24

The following discussion describes how each of these elements of compensation fit into our overall compensation objectives and describes how and why compensation decisions were made with respect to each element based on our